Dissecting the Spectrum, Prevalence, and Molecular Mechanisms of Enhancer Hijacking in Medulloblastoma

剖析髓母细胞瘤中增强子劫持的谱系、患病率和分子机制

基本信息

  • 批准号:
    10471294
  • 负责人:
  • 金额:
    $ 41.06万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-21 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Medulloblastoma (MB) is the most common malignant brain tumor in children. Although aggressive treatments have improved outcomes, many MB patients still die of their disease, and survivors suffer severe long-term side effects from therapy. Thus, more effective and less toxic treatments are desperately needed. Genomics has established that MB is not a single entity, but more accurately a collection of biologically and clinically distinct diseases designated as subgroups: WNT, SHH, Group 3, and Group 4. In contrast to WNT and SHH subgroup MBs, the molecular basis of Group 3 and Group 4, the most common and aggressive forms of MB, remains only partially understood. We recently discovered a series of recurrent structural genomic alterations that relocate normally distal highly active enhancers proximal to the genes encoding GFI1 and GFI1B, resulting in profound GFI1/GFI1B over- expression in affected Group 3 and Group 4 MBs. The remarkable but complex nature of this genetic- epigenetic interplay mitigated by structural alterations leading to misappropriation of enhancer activity and oncogene deregulation, prompted us to designate this phenomenon `enhancer hijacking'. Intensive sequencing efforts have determined that Group 3 and Group 4 MBs exhibit a paucity of recurrent gene- level mutations, yet often harbor extensive structural alterations of unknown significance. In light of these findings, we hypothesize that enhancer hijacking plays a prominent role in the etiology of Group 3 and Group 4 and strategies aimed to systematically identify and mechanistically characterize these events will advance our understanding of these poorly defined subgroups. To test this hypothesis, we propose to: (i) systematically investigate the spectrum and prevalence of enhancer hijacking in MB subgroups; (ii) elucidate the mechanistic basis of prominent enhancer hijacking events contributing to MB, including the role of 3-dimensional genome organization; and (iii) functionally recapitulate MB-associated enhancer hijacking in relevant cellular contexts. The results from these studies will extend beyond poorly understood MB subgroups and aim to yield essential insights into the molecular mechanisms governing oncogene deregulation in cancer and provide a deeper understanding into how noncoding genomic variation contributes to malignancy.
项目总结 髓母细胞瘤是儿童最常见的恶性脑肿瘤。尽管咄咄逼人 治疗改善了结果,许多MB患者仍然死于他们的疾病,幸存者遭受痛苦 严重的长期治疗副作用。因此,更有效和毒性更低的治疗方法是 迫切需要。基因组学已经确定甲基溴不是一个单一的实体,而更准确地说是一个 被指定为亚组的生物学和临床上不同的疾病集合:WNT,SHH,第3组, 与WNT和SHH亚基MBS相比,基团3和基团4的分子基础, 对甲基溴最常见和最具攻击性的形式仍然只有部分了解。我们最近 发现了一系列重复出现的结构基因组改变,这些改变通常发生在高活性的远端 在编码GFI1和GFI1B的基因附近的增强子,导致深刻的GFI1/GFI1B过度表达。 受影响的第3组和第4组MBS的表达。这种基因的非凡而复杂的性质- 通过导致滥用增强子活性的结构变化缓解表观遗传相互作用 以及癌基因的解除管制,促使我们将这种现象命名为增强子劫持。集约化 测序工作已经确定,第3组和第4组MBS显示出缺乏重复基因- 水平突变,但往往隐藏着广泛的结构变化,其意义未知。鉴于这些, 结果,我们假设增强子劫持在第三组和第三组的病因中起着重要作用 旨在系统地确定这些事件并机械地描述这些事件的第四组和战略 将促进我们对这些定义不清的亚群的理解。为了检验这一假设,我们建议 (1)系统地调查甲基溴亚组中增强子劫持的范围和流行率;(2) 阐明导致甲基溴的显著增强子劫持事件的机制基础,包括 三维基因组组织的作用;和(Iii)功能概括的MB相关增强子 在相关的蜂窝环境中劫持。这些研究的结果将不仅仅是糟糕的 了解MB亚群,并致力于对决定 癌基因在癌症中的解除调控,并提供了对非编码基因组如何 变异会导致恶变。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Paul Northcott其他文献

Paul Northcott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Paul Northcott', 18)}}的其他基金

Mapping the Cerebellar Origins of Medulloblastoma Subgroups
绘制髓母细胞瘤亚群的小脑起源图
  • 批准号:
    10587809
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
Cerebrospinal fluid derived circulating tumor DNA as a clinically relevant biomarker in medulloblastoma
脑脊液来源的循环肿瘤 DNA 作为髓母细胞瘤的临床相关生物标志物
  • 批准号:
    10323055
  • 财政年份:
    2021
  • 资助金额:
    $ 41.06万
  • 项目类别:
Cerebrospinal fluid derived circulating tumor DNA as a clinically relevant biomarker in medulloblastoma
脑脊液来源的循环肿瘤 DNA 作为髓母细胞瘤的临床相关生物标志物
  • 批准号:
    10112647
  • 财政年份:
    2021
  • 资助金额:
    $ 41.06万
  • 项目类别:
Dissecting the Spectrum, Prevalence, and Molecular Mechanisms of Enhancer Hijacking in Medulloblastoma
剖析髓母细胞瘤中增强子劫持的谱系、患病率和分子机制
  • 批准号:
    9789850
  • 财政年份:
    2018
  • 资助金额:
    $ 41.06万
  • 项目类别:
Dissecting the Spectrum, Prevalence, and Molecular Mechanisms of Enhancer Hijacking in Medulloblastoma
剖析髓母细胞瘤中增强子劫持的谱系、患病率和分子机制
  • 批准号:
    10247688
  • 财政年份:
    2018
  • 资助金额:
    $ 41.06万
  • 项目类别:
Characterization of ELP1 as a novel SHH medulloblastoma predisposition gene
ELP1 作为新型 SHH 髓母细胞瘤易感基因的表征
  • 批准号:
    10270674
  • 财政年份:
    2003
  • 资助金额:
    $ 41.06万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 41.06万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了